for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

武田薬品工業株式会社

4502.T

現在値

3,674.00JPY

変化

-32.00(-0.86%)

出来高

5,933,000

本日のレンジ

3,636.00

 - 

3,679.00

52週レンジ

3,239.00

 - 

4,365.00

∙ 約20分前の相場を表示しています。

適時開示

Bridgene Biosciences Announces Research Collaboration With Takeda To Discover Small Molecule Drugs For “Undruggable” Targets

March 30 (Reuters) - :BRIDGENE BIOSCIENCES ANNOUNCES RESEARCH COLLABORATION WITH TAKEDA TO DISCOVER SMALL MOLECULE DRUGS FOR “UNDRUGGABLE” TARGETS.BRIDGENE BIOSCIENCES - ELIGIBLE TO RECEIVE MORE THAN $500 MILLION IN POTENTIAL UPFRONT AND MILESTONE PAYMENTS UNDER DEAL.BRIDGENE BIOSCIENCES - FOR ANY VALIDATED TARGETS SELECTED BY TAKEDA, TAKEDA WILL RECEIVE LICENSE TO DEVELOP & COMMERCIALIZE DRUG CANDIDATES.BRIDGENE BIOSCIENCES - CO ALSO ELIGIBLE TO GET ROYALTIES FROM FUTURE SALES OF COMMERCIALIZED DRUGS RESULTING FROM COLLABORATION.BRIDGENE BIOSCIENCES - TAKEDA HAS RIGHT TO INITIATE UP TO FOUR ADDITIONAL RESEARCH PROGRAMS AS PART OF COLLABORATION.BRIDGENE BIOSCIENCES - WILL RECEIVE FROM TAKEDA ONE-TIME UPFRONT PAYMENT FOR ACCESS TO ITS IMTAC TECHNOLOGY. ((Reuters.Briefs@thomsonreuters.com;)).

Novadiscovery Entered Into A New Collaboration With Takeda Pharmaceutical Company Limited

March 26 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::NOVADISCOVERY - ENTERED INTO A NEW COLLABORATION WITH TAKEDA PHARMACEUTICAL COMPANY LIMITED.

Takeda Begins Regulatory Submissions For Dengue Vaccine Candidate In EU And Dengue-Endemic Countries

March 25 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA BEGINS REGULATORY SUBMISSIONS FOR DENGUE VACCINE CANDIDATE IN EU AND DENGUE-ENDEMIC COUNTRIES.TAKEDA PHARMACEUTICAL - INTENDS TO SUBMIT REGULATORY FILINGS FOR TAK-003 IN ARGENTINA, BRAZIL, COLOMBIA, INDONESIA, MALAYSIA DURING 2021.TAKEDA PHARMACEUTICAL - INTENDS TO SUBMIT REGULATORY FILINGS FOR TAK-003 IN MEXICO, SINGAPORE, SRI LANKA AND THAILAND DURING 2021.TAKEDA PHARMACEUTICAL - TAK-003 IS BEING STUDIED FOR PREVENTION OF DENGUE DUE TO ANY DENGUE VIRUS SEROTYPE IN INDIVIDUALS AGES FOUR TO 60.TAKEDA PHARMACEUTICAL - PARTICIPATING IN EMA'S PARALLEL ASSESSMENT OF MEDICINAL PRODUCT, TAKEDA'S DENGUE VACCINE CANDIDATE (TAK-003), FOR USE IN EU.

Evotec And Takeda Enter Strategic RNA Targeting Drug Discovery And Development Alliance

March 22 (Reuters) - Evotec SE <EVTG.DE>::EVOTEC AND TAKEDA ENTER STRATEGIC RNA TARGETING DRUG DISCOVERY AND DEVELOPMENT ALLIANCE.EVOTEC AND TAKEDA ENTER STRATEGIC RNA TARGETING DRUG DISCOVERY AND DEVELOPMENT ALLIANCE.EVOTEC LEVERAGES ITS PROPRIETARY SMALL MOLECULE RNA TARGETING PLATFORM AGAINST MULTIPLE RNA TARGETS ACROSS TAKEDA'S KEY INDICATIONS.EVOTEC RECEIVES RESEARCH FUNDING AND IS ELIGIBLE FOR SUCCESS-BASED MILESTONES AND TIERED ROYALTIES.IS ENTITLED TO TIERED ROYALTIES ON NET SALES OF ANY PRODUCTS RESULTING FROM COLLABORATION..WILL RECEIVE SIGNIFICANT RESEARCH FUNDING AND WILL BE ELIGIBLE TO RECEIVE DISCOVERY, PRE-CLINICAL, CLINICAL, COMMERCIAL AND SALES MILESTONE PAYMENTS OF UP TO US$ 160 M PER PROGRAMME..

Health Canada Approves New Indication For Lung Cancer Treatment Option Alunbrig®

March 17 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::HEALTH CANADA APPROVES NEW INDICATION FOR LUNG CANCER TREATMENT OPTION ALUNBRIG®.TAKEDA CANADA INC. - HEALTH CANADA HAS ISSUED ALUNBRIG(BRIGATINIB TABLETS) MARKETING AUTHORIZATION WITHOUT CONDITIONS.

Subgroup Analysis From Phase 3 Clinical Trial Supports Efficacy Of Maribavir Over Conventional Therapies In Transplant Recipients With Cytomegalovirus Infection

March 15 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::SUBGROUP ANALYSIS FROM PHASE 3 CLINICAL TRIAL SUPPORTS EFFICACY OF MARIBAVIR OVER CONVENTIONAL THERAPIES IN TRANSPLANT RECIPIENTS WITH CYTOMEGALOVIRUS INFECTION (REFRACTORY, WITH OR WITHOUT RESISTANCE).TAKEDA PHARMACEUTICAL - CONTINUES TO INVESTIGATE MARIBAVIR FOR FIRST-LINE TREATMENT OF CMV IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS IN PHASE 3 CLINICAL TRIAL.TAKEDA - TRANSPLANT RECIPIENTS RECEIVING MARIBAVIR EXPERIENCED LOWER RATES OF TREATMENT-RELATED NEUTROPENIA, ACUTE KIDNEY INJURY VERSUS CONVENTIONAL ANTIVIRAL THERAPIES.TAKEDA PHARMACEUTICAL CO LTD - FINDINGS FROM OVERALL TRIAL POPULATION SHOWED STUDY MET ITS PRIMARY ENDPOINT.

Genevant Sciences Announces Global Collaboration And License Agreement With Takeda To Develop Novel Nucleic Acid Therapeutics For Liver Fibrosis

March 15 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::GENEVANT SCIENCES ANNOUNCES GLOBAL COLLABORATION AND LICENSE AGREEMENT WITH TAKEDA TO DEVELOP NOVEL NUCLEIC ACID THERAPEUTICS FOR LIVER FIBROSIS.GENEVANT SCIENCES - CO INITIALLY ELIGIBLE TO RECEIVE UP TO $600 MILLION IN UPFRONT, MILESTONE PAYMENTS, PLUS ROYALTIES ON FUTURE PRODUCT SALES.GENEVANT SCIENCES - TAKEDA HAS EXCLUSIVE RIGHTS TO CO'S LNP TECHNOLOGY FOR A SPECIFIED NUMBER OF SELECTED HEPATIC STELLATE CELLS TARGETS.

Takeda’s Growth And Emerging Markets Business Unit Aims To Deliver Double-Digit Revenue Growth Over Next Decade1

March 11 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA PHARMACEUTICAL - REVENUE GOAL OF JPY 1 TRILLION BY FY2030 REPRESENTS MORE THAN DOUBLING OF CURRENT REVENUE IN GROWTH & EMERGING MARKETS BUSINESS UNIT.TAKEDA PHARMACEUTICAL CO LTD - GEM BU IS TARGETING EXPANSION IN HIGH GROWTH MARKETS SUCH AS BRAZIL, CHINA AND INDIA.

Takeda To Acquire Maverick Therapeutics

March 9 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA TO ACQUIRE MAVERICK THERAPEUTICS TO ADVANCE T-CELL ENGAGER THERAPIES FOR SOLID TUMORS AND EXPAND NOVEL IMMUNO-ONCOLOGY PORTFOLIO.TAKEDA PHARMACEUTICAL CO LTD - AFTER DEAL, MAVERICK EMPLOYEES WILL JOIN TAKEDA'S RESEARCH & DEVELOPMENT ORGANIZATION.TAKEDA PHARMACEUTICAL CO LTD - EXERCISED OPTION TO ACQUIRE MAVERICK FOR UPFRONT PAYMENT AS WELL AS MILESTONES TOTALING UP TO $525 MILLION.

Takeda Secures Global Rights From Ovid Therapeutics To Develop, Commercialize Soticlestat

March 3 (Reuters) - Ovid Therapeutics::OVID THERAPEUTICS - TAKEDA SECURES GLOBAL RIGHTS FROM CO TO DEVELOP, COMMERCIALIZE SOTICLESTAT TO TREAT DRAVET SYNDROME, LENNOX-GASTAUT SYNDROME.OVID THERAPEUTICS - CO IS ELIGIBLE TO GET UPTO $856 MILLION IN PAYMENTS, INCLUDING UPFRONT PAYMENT OF $196 MILLION.OVID - ELIGIBLE TO GET UPTO $660 MILLION UPON ACHIEVING MILESTONES, TIERED ROYALTIES FROM LOW DOUBLE-DIGITS & UPTO 20% ON SALES OF SOTICLESTAT.OVID THERAPEUTICS - TAKEDA PLANS TO INITIATE PHASE 3 STUDIES IN CHILDREN, ADULTS WITH DRAVET SYNDROME & LENNOX-GASTAUT SYNDROME IN CALENDAR YEAR Q2 2021.OVID THERAPEUTICS - ORIGINAL 2017 COLLABORATION BETWEEN CO & TAKEDA TO CONCLUDE; CO WILL HAVE NO FURTHER DEVELOPMENT OR MILESTONE OBLIGATIONS.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up